Status:

TERMINATED

Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Lead Sponsor:

University of Maryland, Baltimore

Collaborating Sponsors:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions:

Alcohol Abuse

Alcoholism

Eligibility:

All Genders

18-25 years

Phase:

PHASE2

Brief Summary

This study will evaluate the efficacy of ondansetron + BASICS Plus in reducing severe or binge drinking among emerging adults. BASIC Plus (Brief Alcohol Screening and Intervention for College Students...

Detailed Description

We propose to conduct a 9 week study to test the efficacy of ondansetron in a heavy drinking (non-dependent) emerging adult population. We will enroll individuals between the ages of 18 and 25 years a...

Eligibility Criteria

Inclusion

  • White Males and females who have given written informed consent.
  • Ages 18 through 25;also, patients must weigh ≥40 kg and ≤140 kg.
  • Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters.
  • At least an average of one episode of binge or heavy drinking per week in the past month prior to enrollment. For men and women, that is ≥5 and ≥4 drinks/drinking day, respectively.They also need to report at least one day of heavy drinking within the 7 days prior to randomization.
  • The pregnancy test for females at intake must be negative. Additionally, women of childbearing potential must be using an acceptable form of contraception.
  • Literate in English and able to read, understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments.
  • Answer an advertisement in the newspaper/radio/television, and express a wish to stop heavy drinking.
  • Willingness to participate in behavioral treatments to stop heavy drinking

Exclusion

  • Please contact site for additional information

Key Trial Info

Start Date :

September 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2017

Estimated Enrollment :

74 Patients enrolled

Trial Details

Trial ID

NCT00890149

Start Date

September 1 2015

End Date

March 1 2017

Last Update

May 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Neurobehavioral Center

Columbia, Maryland, United States, 21045